Literature DB >> 1397748

Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth.

W Creutzfeldt1, R Lamberts.   

Abstract

The development of gastric enterochromaffin-like (ECL)-cell hyperplasia in humans may be associated with extreme hypergastrinaemia, as occurs in Zollinger-Ellison syndrome (ZES) and pernicious anaemia (type A gastritis). More recently, endocrine cell hyperplasia has been found in all forms of chronic atrophic gastritis and even in cases of focal atrophy. Serum gastrin levels, non-antral gastric endocrine (argyrophil) cell growth, and the severity and type of concomitant gastritis were monitored in 66 unoperated and 8 antrectomized patients with poorly responsive peptic ulcer or reflux oesophagitis during up to 5 years' treatment with high-dose omeprazole, 40 mg daily. A small subgroup of patients (23%) had serum gastrin concentrations of more than four times the normal upper limit. These patients also had hyperplasia of the gastric argyrophil cells. More importantly, the same subgroup of patients had high-grade (atrophic) gastritis. Micronodular hyperplasia of argyrophil cells was significantly more frequent in biopsies showing atrophic gastritis (48%) than in biopsies showing only superficial gastritis (3.6%). It is concluded that, as previously demonstrated in untreated patients with gastric ulcer, the argyrophil cell hyperplasia observed during high-dose omeprazole therapy is related to the progression of chronic atrophic gastritis rather than to serum gastrin levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397748     DOI: 10.1159/000200920

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  8 in total

Review 1.  Hyperplastic proliferations of enteroendocrine cells.

Authors:  Yogeshwar Dayal
Journal:  Endocr Pathol       Date:  1994-03       Impact factor: 3.943

Review 2.  Role of gastrin-peptides in Barrett's and colorectal carcinogenesis.

Authors:  Eduardo Chueca; Angel Lanas; Elena Piazuelo
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

Review 3.  Immunological and morphogenic basis of gastric mucosa atrophy and metaplasia.

Authors:  Gerhard Faller; Thomas Kirchner
Journal:  Virchows Arch       Date:  2004-12-04       Impact factor: 4.064

4.  Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.

Authors:  J Dent; N D Yeomans; M Mackinnon; W Reed; F M Narielvala; D J Hetzel; E Solcia; D J Shearman
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

Review 5.  Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.

Authors:  W Creutzfeldt
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 6.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

7.  Hypergastrinemia and enterochromaffin-like cell hyperplasia.

Authors:  G Delle Fave; M Marignani; A Moretti; G D'Ambra; G Martino; B Annibale
Journal:  Yale J Biol Med       Date:  1998 May-Aug

Review 8.  The consequences of hypergastrinemia.

Authors:  W Creutzfeldt
Journal:  Yale J Biol Med       Date:  1994 May-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.